GENB

H.C. Wainwright initiated coverage on Generate Biomedicines with a new price target

Piper Sandler initiated coverage on Generate Biomedicines with a new price target

Morgan Stanley initiated coverage on Generate Biomedicines with a new price target

Cantor Fitzgerald initiated coverage on Generate Biomedicines

Guggenheim initiated coverage on Generate Biomedicines with a new price target

Goldman initiated coverage on Generate Biomedicines with a new price target

New insider Pioneering Medicines 02, Llc claimed ownership of 1,562,500 shares (SEC Form 3)

Chief Executive Officer Nally Michael bought $240,000 worth of shares (20,000 units at $12.00), increasing direct ownership by 4% to 572,707 units (SEC Form 4)

SEC Form 4 filed by Director Vessey Rupert

Chief People Officer Grous Beth bought $4,800 worth of shares (300 units at $16.00) (SEC Form 4)

SEC Form 4 filed by Director Arnold Frances

SEC Form 4 filed by Chief Legal Officer & GC Martin Sean

SEC Form 4 filed by Chief Medical Officer Lee Laurie Anne

SEC Form 4 filed by Director Simonian Nancy A

President & CFO Silvers Jason bought $32,000 worth of shares (2,000 units at $16.00) (SEC Form 4)

Director Afeyan Noubar converted options into 32,969,159 shares and bought $75,000,000 worth of shares (4,687,500 units at $16.00) (SEC Form 4)

SEC Form 4 filed by Chief Technology Officer Grigoryan Gevorg

Chief Executive Officer Nally Michael converted options into 658,327 shares (SEC Form 4)

Director Bancel Stephane converted options into 724,160 shares (SEC Form 4)

Director Mendillo Jane L bought $24,000 worth of shares (1,500 units at $16.00) (SEC Form 4)

SEC Form 4 filed by Director Fanucci Marsha

SEC Form 4 filed by Director Parker Paul Gray

Director Afeyan Noubar converted options into 32,969,159 shares and bought $75,000,000 worth of shares (4,687,500 units at $16.00) (SEC Form 4)

Generate Biomedicines Inc. filed SEC Form 8-K: Financial Statements and Exhibits